The case for an injectable route over theatre

'Do I actually need an operation?' is the question most patients bring to a cartilage consultation — and for a specific group of knee patients, the honest answer is increasingly: not necessarily.

ChondroFiller is administered as a single outpatient injection under ultrasound guidance, with no incision, no general anaesthetic, and no hospital admission. That is not a marginal convenience difference; it places the treatment at a fundamentally different point on the invasiveness spectrum from arthroscopic cartilage repair or open procedures, both of which require theatre time, anaesthetic risk, and weeks of post-operative recovery.

The distinction matters beyond logistics because ChondroFiller is not a symptom-masking injection in the way that, say, a lubricant or a pain-relief agent might be. It is designed to promote structural repair at the defect site — doing biological work that previously required surgical access to achieve.

That said, the 'instead of surgery' case rests on patient selection. The pathway is realistic for focal cartilage lesions where the surrounding cartilage retains reasonable quality and the joint's own regenerative capacity remains intact. It is not a blanket alternative to every form of knee cartilage surgery, and end-stage or bone-on-bone disease sits outside this indication.

How the scaffold recruits the body's own cells

Microfracture drills into bone to trigger a bleeding response; MACI harvests cartilage tissue, cultures cells in a laboratory, and reimplants them weeks later. ChondroFiller works by neither route.

The material itself is a cell-free, acid-extracted Type I collagen liquid — no donor cells, no growth factors, no laboratory processing required. Once placed into the defect site, it meets the joint's neutral pH and self-polymerises within approximately 3–5 minutes, forming a dimensionally stable three-dimensional scaffold that fills the space.

That scaffold does not repair cartilage directly. What it provides is a structured framework — an acellular matrix — into which the patient's own progenitor cells from the surrounding synovium and subchondral bone can migrate. Over subsequent months, those recruited cells produce new cartilage matrix, supported by the collagen lattice. This is the mechanism clinicians describe as acellular matrix-induced chondrogenesis: the scaffold promotes endogenous repair rather than delivering a repair agent itself.

The practical consequence of this additive approach is that the body does the biological work; ChondroFiller supplies the architecture that makes that work possible. This is why it is described as regenerative — supporting the body's own repair processes at the defect site — rather than palliative in the way a lubricant is, or ablative in the way microfracture is. The collagen lattice gradually resorbs as newly formed tissue consolidates around it.

What the injection appointment actually involves

The appointment takes place in a standard clinic room — the same kind of setting familiar to anyone who has previously had a steroid or hyaluronic acid injection into a joint. There is no theatre preparation, no surgical wound care, and no overnight admission to arrange beforehand.

Delivery is image-guided: the treating clinician uses ultrasound to visualise the defect in real time, positioning the needle precisely before releasing the collagen material directly into the lesion. That precision matters because ChondroFiller arrives as a liquid rather than a pre-formed solid implant; it conforms to the defect's geometry on contact, filling the space without requiring the joint to be opened or the lesion to be shaped mechanically beforehand.

Post-procedure guidance centres on graduated offloading. Most patients are advised to reduce load on the joint in the days immediately following the injection and to increase activity progressively over the subsequent weeks as the scaffold consolidates and the body's own repair processes establish themselves. This is a materially lighter recovery demand than the weeks of crutch-dependent rehabilitation typically required after microfracture or reconstructive cartilage surgery — though the specific timeline should be confirmed with the treating clinician at assessment, as it varies with defect size and joint.

Who is a suitable candidate — and who is not

The clearest positive indicator is a focal cartilage lesion — typically post-traumatic damage or osteochondritis dissecans — in a joint where the bone surfaces still have adequate spacing and the surrounding cartilage retains structural integrity. Defects up to approximately 6 cm² fall within the documented treatment range for the injectable pathway. No strict upper age limit applies: because the injectable form coats the joint surface rather than filling a surgically bounded pocket, it has wider application than the Liquid Cartilage surgical pathway, which is reserved for contained focal defects where the body's regenerative capacity is preserved.

End-stage arthritis — bone-on-bone loss across the joint surface — sits outside the indication. The scaffold depends on a residual biological environment capable of supporting cell migration and repair; that environment is absent when cartilage has been lost entirely, and placing a scaffold into such a joint would not produce a regenerative outcome.

Patient biology and defect characteristics introduce individual variability at the outcome level. The 70–85% meaningful-relief figure at 3–5 years describes a population average across treated cohorts, not a guaranteed personal result.

Patients who fall between these poles — significant OA but not yet bone-on-bone — may find the candidacy question answered differently, because combination protocols exist precisely for that clinical picture. ChondroFiller can be paired with Arthrosamid, a permanent polyacrylamide hydrogel that integrates into the synovial membrane to act as a mechanical cushion; it addresses pain from joint-space narrowing through a distinct, non-regenerative mechanism rather than augmenting the collagen scaffold itself. A further option adds autologous MSCs to the injection sequence — a more intensive protocol appropriate for specific clinical presentations, not a routine escalation. Both require individual clinical assessment to determine whether the overall picture justifies them.

What the clinical evidence shows

The functional improvement data from published multi-centre cohorts give a concrete reference point. Across knee cases, mean IKDC scores have risen by approximately 30 points — a shift that moves most patients from the 'significant limitations' to the 'moderate or minimal limitation' band on that validated scale. In hip patients, equivalent work shows a mean Harris Hip Score improvement of 33 points.

MRI-based MOCART scoring — a validated method for assessing defect fill and tissue quality — has returned scores of 70 to 87 across multiple centres, providing objective structural evidence that tissue is present at the repair site rather than symptom relief in the absence of any filling.

At the population level, 70 to 85% of treated patients achieve meaningful symptom relief sustained to three to five years, a figure reported consistently across knee, hip, and smaller-joint applications in cohort data spanning more than 19,000 procedures globally. A 2025 peer-reviewed study by Demmer, examining intra-articular scaffold delivery in larger joints, adds further depth to what had been a predominantly registry-based literature.

The evidence base carries acknowledged limits. No large randomised controlled trial comparing ChondroFiller against a sham injection or against microfracture has yet been completed — the trial design most clinicians regard as the gold standard remains outstanding. The available data derive primarily from observational cohorts, some at centres with a direct interest in the product. The 70 to 85% figure describes what treated groups have experienced in those series; individual outcomes vary with defect size, surrounding cartilage quality, and patient biology.

ChondroFiller versus other knee injection and surgical options

The clearest point of separation between ChondroFiller and hyaluronic acid (HA) viscosupplementation is mechanism: HA lubricates the joint and may reduce pain by restoring synovial fluid viscosity, but it does not provide a structural scaffold or recruit cells to a defect site. Symptom relief and structural repair are different objectives, and HA addresses only the former.

Arthrosamid, as described in the candidacy section above, integrates into the synovial membrane as a permanent mechanical hydrogel cushion. It may reduce pain from joint loading, but it does not target the cartilage lesion directly — a distinction that matters when the clinical goal is structural fill rather than pain modulation alone.

The more significant contrast is with surgical alternatives. Both microfracture and MACI require arthroscopy under general anaesthetic, hospital admission, and a rehabilitation period during which weight-bearing is typically restricted for several weeks. For suitable focal defects, the injectable ChondroFiller pathway removes all of those elements from the recovery calculation.

ChondroFiller is not available through the NHS and is not covered by standard private medical insurance in the UK; it is also not FDA-approved in the United States. Patients considering it can book a specialist assessment at London Cartilage Clinic on Harley Street via londoncartilage.com. The questions that most directly shape that assessment — defect size and grade, the quality of surrounding cartilage, and whether structural repair or symptom control is the primary goal — are the same whether the pathway ultimately chosen is injectable or surgical.